Compugen at Stifel 2026 Healthcare Conference: pipeline, cash and catalysts

On 10 November 2026, Compugen Ltd. (CGEN) addressed its investors at the Stifel 2026 Healthcare Conference. The biotech company unveiled a two-pronged approach: advancing its internal cancer drug COM701 and leveraging partnerships with major drugmakers. CGEN emphasized its robust cash position, which stretches into 2029, providing ample time to fund crucial programs through key 2027 and 2028 data events.

At the heart of CGEN's strategy lies its lead internal program, COM701, which has successfully completed enrollment in the 60-patient MAIA-ovarian study. The interim readout from this study is anticipated in the first quarter of 2027. The company is confident in the potential of COM701, anticipating over $1 billion in combined milestone and royalty potential from collaborations with AstraZeneca and Gilead.

CGEN's AI-powered Unigen platform has been validated by its partner programs and is now being expanded into UnigenX, focusing on T-cell engager target discovery. This platform has already produced targets that have progressed through internal development and strategic collaborations. The company highlighted that UnigenX targets tumor-associated antigens, aiming to identify clean, tumor-specific targets akin to DLL3, which has become a benchmark in T-cell engager development for small cell lung cancer.

CEO Eran Ophir explained that CGEN employs a computational, AI-based discovery engine to uncover new immuno-oncology targets and direct them into either its own pipeline or partnerships. The Unigen platform's validation by strategic collaborations has generated more than $1 billion in potential milestones and royalties.

The company has diversified its economic landscape through major collaborations. AstraZeneca's rilvegostomig program carries an additional $195 million in milestone potential and mid-single-digit royalties, with a peak sales potential of over $5 billion. Gilead's GS-0321 program has already generated $90 million for CGEN and carries $758 million in additional milestone potential, coupled with low double-digit tier royalties.

Despite the competitive landscape in ovarian cancer and the need for clinical data to solidify its case, CGEN's cash runway extends into 2029. The company's financial position is solid, with a cash balance that supports operations well into the future. InvestingPro data reveals that CGEN holds more cash than debt on its balance sheet and maintains a strong liquidity ratio of 5.72. Its impressive gross profit margin of 87% underscores the company's financial health.

The most immediate internal catalyst for CGEN is the MAIA-ovarian study, which has completed enrollment. This 60-patient adaptive platform study of COM701 in platinum-sensitive ovarian cancer aims to demonstrate a median progression-free survival of six months in the treatment arm, compared to approximately four months in the control arm.

The revised control arm median reflects updated data from studies like TIDAL and DUO-O, as well as changes in treatment patterns, including the increased use of PARP inhibitors and bevacizumab in earlier lines.

Ophir emphasized that COM701 targets a distinct checkpoint, PVRIG, which affects a different stage of the cancer immunity cycle. The program has shown activity in scenarios where checkpoint drugs typically face challenges, such as platinum-resistant ovarian cancer, PD-L1-negative tumors, and heavily pretreated patients. COM701's safety profile remains clean, with minimal discontinuation rates.

The addressable patient population for COM701 is estimated at around 10,000 patients annually, potentially increasing if the drug is tested in combinations or moved into earlier treatment lines. Despite competition and class-wide skepticism, COM701 presents an attractive maintenance market with several antibody-drug conjugate programs in phase 3 development.